White House strategy to reduce pharmaceutical prices faces backlash from the industry, which cautions against the ‘far-reaching’ proposals
The US pharmaceutical industry has concerns about President Trump’s blueprint to address the high cost of medicines in America, unveiled in a speech in the White House’s iconic Rose Garden on 11 May. The administration’s new strategy explicitly targets ‘excessively high drug prices, foreign freeloading, and a system rigged to reward list price increases’.